Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 787.37

+3.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	4/28/2016 2:33:26 PM
	of 3559

RE: AMGN Repatha patents Delayed thought on this issue, ...blind was able to see that Praluent infringe 3 Repatha "designee" patents. Those 3 patents cover antibody interaction with target PCSK9 (certain epitope/a. acid residues in protein 3D structure). So, can patent cover surrogate substrate-target interaction, and is this "invention" true invention? For instance, point of interaction between small molecule substrate and activity pocket of enzyme can be described from crystal structure, and protect invention from any replication. Any small molecule that bind this pocket and interact with specific "a. acids residue" infringe innovation. I am not sure is there any similar case in bio-sector that can explain similar IP procedure and right protection??? Does anyone have one?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next